Navigation Links
Drugs from Biogen Idec and Merck are the Most Promising Therapies in Development in the Acute Heart Failure Market
Date:2/2/2009

Overall Market for Acute Heart Failure Therapies Will More Than Double to $768 Million in 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Biogen Idec's Adentri and Merck's rolofylline are the most promising therapies in development for acute heart failure, according to surveyed experts. Scios/Johnson & Johnson's Natrecor and Daiichi Sankyo's Hanp have also added considerable value to the acute heart failure market in recent years and will continue to do so through 2017.

The new Pharmacor report entitled Acute Heart Failure finds that the launch of Adentri and rolofylline, along with EKR Therapeutics' ularitide, will be the primary drivers of growth in the acute heart failure drug market over the next decade. Growth will also be driven by an increase in the number of diagnosed events of acute heart failure as a result of the rising population of elderly people, improved diagnosis methods and increased survival following acute myocardial infarction.

The report forecasts that the acute heart failure market will more than double, from $354 million in 2007 to $768 million in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The market for acute heart failure is modestly sized because the dominant therapies -- loop diuretics and nitrate vasodilators -- are some of the oldest agents in cardiology and, as a result, are generically available and inexpensive.

"Despite the significant unmet need, research and development pipelines for acute heart failure are not as robust as those for other cardiovascular indications such as hypertension and dyslipidemia," said Decision Resources Analyst Amir Mobasheri. "As a result, any novel agent that can demonstrate improvements in safety and mortality and shows efficacy in preventing future acute heart failure episodes will be well received by physicians and patients."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained

in this document may be trademarks or registered trademarks of their

respective holders.

    For more information, contact:

    Decision Resources                        Decision Resources, Inc.
    Christopher Comfort                       Elizabeth Marshall
    781-296-2597                              781-296-2563
    ccomfort@dresources.com                   emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... PhishLine, the best-in-class, enterprise level ... as Vice President of Sales. Cifolelli’s primary responsibilities include management of the ... rapidly expanding field of organizational social engineering. , “We are delighted to ...
(Date:5/24/2016)... Orion, Clarkston Michigan (PRWEB) , ... May 24, ... ... new Certified Nurse Midwife, Roberta Jordan. , Roberta Jordan is a Certified ... degree from Grand Valley State University and then went on to complete her ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... advisory organization, is pleased to welcome new Partner Firm Austin & Co., Inc. ... consultative approach to insurance, employee benefits, HR consulting, benefits technology, and beyond. ...
(Date:5/24/2016)... ... 2016 , ... Local engineering firm, Timmons Group, announced the ... in Woodbridge, VA. The project includes a brand new operating room addition ... new 2 story building houses the Central Sterile department, Sterile prep area and ...
(Date:5/24/2016)... ... ... Mental health watchdog Citizens Commission on Human Rights (CCHR) of Georgia, ... Szasz, is continuing its protest against the use of electroshock (ECT) on children with ... opening of the exhibit follows CCHR’s recent protest at the annual convention of the ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016 Niederländische Chirurgen ... die es Ärzten erlaubt, ihre Expertise weltweit zu ... kombiniert Live Streaming mit einer Instant-Messaging-Funktion und der ... Mediziner in Europa, Afrika, Asien und den ... die Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)...   , ... primären Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung ... plus guter , Reinigung des ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... von der MORA-Studie der Phase III für NER1006 ...
Breaking Medicine Technology: